Volume 23, Number 3—March 2017
Research Letter
Successful Treatment of Human Plague with Oral Ciprofloxacin
Titus Apangu, Kevin Griffith1, Janet Abaru, Gordian Candini, Harriet Apio, Felix Okoth, Robert Okello, John Kaggwa, Sarah Acayo, Geoffrey Ezama, Brook Yockey, Christopher Sexton, Martin Schriefer, Edward Katongole Mbidde, and Paul S. Mead
Table
Demographic and clinical characteristics of 5 patients with culture-confirmed plague (Yersina pestis infection) who were treated successfully with oral ciprofloxacin, Uganda, 2011–2014
| Patient no. | Age, y/sex | Length of illness, d* | Symptoms | Laboratory evidence | Ciprofloxacin dose, mg† |
|---|---|---|---|---|---|
| 1 | 10/F | 7 | Fever, left axillary bubo | Bubo, blood cultures positive | 250 |
| 2 | 52/F | 4 | Fever, right axillary bubo | Bubo, blood cultures positive | 650 |
| 3 | 27/F | 1 | Fever, left inguinal bubo | Bubo, blood cultures positive | 750 |
| 4 | 36/M | 1 | Fever, left axillary bubo | Blood culture positive | 625 |
| 5 | 13/M | 6 | Fever, chest pain, cough, blood-tinged sputum | Sputum culture positive, blood culture negative | 375 |
*At time treatment was sought.
†Orally, twice daily; ≈15 mg/kg bodyweight with a maximum of 750 mg.
1Current affiliation: Fort Lewis College, Durango, Colorado, USA.
Page created: February 17, 2017
Page updated: February 17, 2017
Page reviewed: February 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.